Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
XOMA Royalty Corporation ( (XOMA) ) has shared an announcement.
On March 18, 2026, XOMA Royalty reported its fourth-quarter and full-year 2025 results, posting $50.5 million in cash receipts, including $33.6 million in royalties and $16.9 million in milestones, a 9% increase in total receipts and a 68% jump in royalties versus 2024. The company achieved positive cash flow from operations, repurchased $16 million of its stock, and highlighted a growing base of commercial royalties from products such as VABYSMO and OJEMDA.
During 2025 and early 2026, XOMA expanded its portfolio by adding 22 assets and two platform technologies, completing or structuring seven acquisitions and amending its collaboration with Takeda to secure royalty and milestone rights across nine development-stage assets. With 14 programs now in registrational studies and key 2026 readouts and regulatory milestones expected for assets including volixibat, ersodetug, seralutinib, OJEMDA, and MIPLYFFA, the company signaled a potentially broader and more diversified royalty stream that could enhance free cash flow and shareholder value over the coming years.
The most recent analyst rating on (XOMA) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on XOMA Royalty Corporation stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
Overall score reflects mixed financial performance (strong margins but elevated leverage and weak cash-flow trends) as the primary driver, with neutral technical signals and a high P/E weighing on the outlook; positive corporate developments provide a modest offset.
To see Spark’s full report on XOMA stock, click here.
More about XOMA Royalty Corporation
XOMA Royalty Corporation, based in Emeryville, Calif., is a biotech royalty aggregator that acquires economic interests in biopharmaceutical royalties and milestones. The company focuses on commercial and late-stage clinical assets across multiple therapeutic areas, seeking diversified, non-dilutive cash flows from partnered programs worldwide.
Average Trading Volume: 412,316
Technical Sentiment Signal: Sell
Current Market Cap: $334.3M
For a thorough assessment of XOMA stock, go to TipRanks’ Stock Analysis page.